ACET vs FATE vs CRSP vs CELC vs ILMN

For growth investors, Illumina, Inc.

(ILMN) is the stronger pick with -0. 8% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). Illumina, Inc. (ILMN) offers the better valuation at 29. 5x trailing P/E (30. 8x forward), making it the more compelling value choice. Analysts rate Adicet Bio, Inc. (ACET) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Celcuity Inc.

(CELC) delivered a total return of +235. 2%, compared to -97. 7% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: CELC returned +519. 7% versus ACET's -92. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Illumina, Inc.

(ILMN) is the lower-risk stock at 0. 99β versus Adicet Bio, Inc. 's 2. 08β — meaning ACET is approximately 111% more volatile than ILMN relative to the S&P 500. On balance sheet safety, Adicet Bio, Inc. (ACET) carries a lower debt/equity ratio of 9% versus 194% for Celcuity Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Illumina, Inc.

(ILMN) is pulling ahead at -0. 8% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -49. 1% for CRISPR Therapeutics AG. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FATE: 167.

0% to $5. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Illumina, Inc.

(ILMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 99)). Adicet Bio, Inc. (ACET) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ILMN: +18. 6%, ACET: -92. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.